Reference is made to the stock exchange announcement by Lifecare ASA (the
"Company") on 12 November 2025 regarding the resolution by the Extraordinary
General Meeting held on the same date to reduce the par value of the Company's
shares to NOK 0.10, in order to facilitate the subscription of shares and
exercise of warrants in connection with the contemplated partially
underwritten rights issue announced by the Company on 22 October 2025.
The share capital reduction has now been registered with the Norwegian
Register of Business Enterprises. The Company's new share capital is NOK
1,906,097.30 divided into 19,060,973 shares, each with a par value of NOK
0.10.
About us
Lifecare ASA is a medical sensor company developing technology for sensing and
monitoring of various body analytes. Lifecare's focus is to bring the next
generation of Continuous Glucose Monitoring systems to market. Lifecare
enables osmotic pressure as sensing principle. Lifecare's sensor technology is
suitable for identifying and monitoring the occurrence of a wide range of
analytes and molecules in the human body and in pets.
Contacts
For further information, please contact:
Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40
Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42
This information is subject to disclosure under the Norwegian Securities
Trading Act, ยง5-12. The information was submitted for publication, through the
agency of the contact persons set out above, at 2025-12-31 10:40 CET.